AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00855101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: 6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
Study NCT01441492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drains
Description: A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
Study NCT03922997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
Study NCT01183533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase (iv t-PA)
Description: 0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
Study NCT02034149 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: general management
Description: All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
Study NCT02034149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general management
Description: All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
Study NCT02034149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management
Description: Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
Study NCT01441492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drains
Description: A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
Study NCT05663684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Hydrochloride ophthalmic solution, USP 0.5%
Description: One drop instilled in one eye, randomly chosen, as topical anesthetic
Study NCT05663684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Description: One drop instilled in one eye, randomly chosen, as control placebo
Study NCT03573050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIV-TDS 13.3 mg/24 h
Description: 5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
Study NCT03573050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon® 13.3 mg/24 hours transdermal patch
Description: 5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
Study NCT00967499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting.
Study NCT00967499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery.
Study NCT01596114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping treatment with TKI
Description: stopping until loss of MMR
Study NCT02270814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study NCT02340819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
Study NCT02053389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Decision Aid
Description: The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation.
Study NCT02270814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02270814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02270814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study NCT03711734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture + Standard of Care
Description: Acupuncture is a nonpharmacologic pain management modality that has been shown to provide superior analgesia for acute pain. This will be combined with our facility's standard of care anesthesia and pain management plan.
Study NCT03782207 — intervention group
Intervention type: DRUG
Intervention: Atezolizumab
Description: Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
Study NCT03687957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-7-hyFc
Description: -Given by intramuscular injection
Study NCT03687957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: -Given by intramuscular injection
Study NCT03687957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Standard of care
Study NCT03565978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAMA solution
Description: Use of BAMA cardiac post-discharge management solution for patients education and follow up management
Study NCT03687957 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care
Study NCT03687957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: * Week 1 (prior to the 1st dose of rhIL-7-hyFc)~* Week 2 (one week after rhIL-7-hyFc)~* Week 3 (two weeks after rhIL-7-hyFc)~* Week 4 (three weeks after rhIL-7-hyFc)~* Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~* Week 14 (one week after rhIL-7-hyFc)~* Week 16 (three weeks after rhIL-7-hyFc) - optional~* Week 45 (eight weeks after the last dose of rhIL-7-hyFC)~* If ADA or NADA is observed in week 45, additional blood collections will be required every 2 months in order to monitor ADA/NADA levels until it decreases to the basal level~* At the time of tumor progression
Study NCT01928394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01928394 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT01928394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Study NCT04069468 — intervention group
Intervention type: DEVICE
Intervention: TheraSphere
Description: Participants will receive treatment with TheraSphere in accordance with Instructions for Use
Study NCT02034149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-assisted management
Description: The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
Study NCT03126409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-Touch vein harvesting technique
Description: The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
Study NCT03126409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vein harvesting
Description: During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
Study NCT04175886 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: Patients will be treated with tofacitinib
Study NCT05575895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Ingestion of the energy drink (Red Bull®)
Description: Ingestion of 250 ml of the energy drink (Red Bull®)
Study NCT05575895 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Ingestion of mineral water
Description: Ingestion of 250 ml of mineral water (Minalba®)
Study NCT01359371 — intervention group
Intervention type: BEHAVIORAL
Intervention: Peer telephone cessation counseling
Description: For Veterans who received the inpatient Tobacco Tactics intervention, trained volunteers initiated follow-up telephone cessation counseling at 2, 14, 21 and 60 days after in-patient discharge; three attempts were made per time point.
Study NCT01156116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP mask
Description: The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________
Study NCT01156116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo tablet
Study NCT05576051 — intervention group
Intervention type: OTHER
Intervention: patterns of use of combination therapy and monotherapy
Study NCT02053389 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written decision aid
Description: A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer.
Study NCT01769690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS stimulator setting alteration
Description: 2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy
Study NCT01769690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality simulator
Description: This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test.
Study NCT02619019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
Study NCT01193153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: monthly by i.m. injection for 15 months
Study NCT01193153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: 78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
Study NCT00684528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily
Description: 500 mg thrice daily
Study NCT00684528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 1500 mg daily
Description: 500 mg thrice daily
Study NCT00684528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Janufer (Janumet)
Description: Titration up to 1500/150 mg daily
Study NCT00921830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
Study NCT04008394 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR T cells
Description: Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
Study NCT03097237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain rye
Description: Cereal products based on wholegrain rye
Study NCT03097237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined wheat
Description: Cereal products based on refined wheat
Study NCT04553835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS) for schizophrenia patients
Description: A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Schizophrenia patients in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on the weekday basis (a total of 15 sessions) with one session (40 minutes) per weekday.
Study NCT04553835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No RAS for schizophrenia patients
Description: The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
Study NCT00920296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: GSK drug
Study NCT00906035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole 200mg and Aspirin 25mg bid:
Description: All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
Study NCT00906035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyridamole 200 mg bid
Description: All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
Study NCT00906035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 25 mg bid
Description: All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
Study NCT01007344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flaxseed
Description: 1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
Study NCT01007344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whole wheat flour
Description: 1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
Study NCT00711542 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous bone marrow-derived progenitor cells
Description: intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
Study NCT00711542 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo medium
Description: intracoronary infusion of placebo medium
Study NCT04249388 — intervention group
Intervention type: OTHER
Intervention: No Intervention, just observation
Description: No Intervention, just observation
Study NCT04553835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAS for at-risk individuals
Description: A mobile application, metronome beats developed by Stonekick Limited, will be used to give RAS when the participant executes the movement. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo (beats per minute). For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. At-risk individuals in the experimental group will undergo upper limb movement training with the aid of RAS. The intervention protocol will last for 3 weeks on daily basis (a total of 21 sessions), with one training session (40 minutes) per day.
Study NCT04553835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No RAS for at-risk individuals
Description: The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
Study NCT02619019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
Study NCT02087917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HS-25
Description: Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
Study NCT02580448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel
Description: Seviteronel given daily with evening meal in 28 day cycles
Study NCT00423254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSMA/PRAME
Description: Low dose
Study NCT00423254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSMA/PRAME
Description: high dose
Study NCT01130818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
Study NCT01130818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution
Study NCT01130818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single dose, solid formulation, 50 mg (2\*25 mg/capsule), fasting
Study NCT01130818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0492
Description: single dose, solid formulation, 50 mg (2\*25 mg/capsule), after high fat breakfast
Study NCT00789919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delivery of infant
Description: Vaginal delivery or cesarean section, whichever is indicated
Study NCT02883088 — intervention group
Intervention type: PROCEDURE
Intervention: Frequency Domain - Optical Coherence Tomography (FD-OCT)
Description: FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
Study NCT04104789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovanaze Nasal Spray
Description: Intra-nasal local anesthetic
Study NCT02619019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
Study NCT04005820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiologic Centralized Review
Description: The patient's imaging will be examined in one of the examination centers
Study NCT04005820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue sample (tumor, sung, urine)
Description: all the samples will be made during the patients care
Study NCT03451864 — intervention group
Intervention type: PROCEDURE
Intervention: Vaginal delivery
Description: classic vaginal delivery
Study NCT03451864 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean Section
Description: routine lower segment cesarean scetion